Drugs / TOZASERTIB
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00500006 | Oct → Nov 2007 | chronic myeloid leukemia, precursor lymphoblastic lymphoma/leukemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00111683 | Jun 2005 → May 2008 | B-cell acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, myelodysplastic syndrome | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02532868 | May 2005 → Jan 2008 | cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00099346 | Jan 2005 → Apr 2007 | colorectal cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00405054 | Dec 2006 → Jun 2009 | leukemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00290550 | Jun 2006 → May 2007 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-11-20 | Vertex Pharmaceuticals Incorporated | Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data vrtx.com ↗ |
| 2006-12-21 | Vertex Pharmaceuticals Incorporated | Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients with Treatment-Resistant Forms of Advanced Leukemias vrtx.com ↗ |
| 2006-12-11 | Vertex Pharmaceuticals Incorporated | Merck and Vertex Announce Phase I Results for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity in Patients with Treatment-Resistant Forms of Advanced Leukemias and Myeloproliferative Disorders vrtx.com ↗ |
| 2006-04-05 | Vertex Pharmaceuticals Incorporated | Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680) vrtx.com ↗ |
| 2005-12-07 | Vertex Pharmaceuticals Incorporated | Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study vrtx.com ↗ |
| 2005-12-07 | Vertex Pharmaceuticals Incorporated | Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study vrtx.com ↗ |
| 2005-06-17 | Vertex Pharmaceuticals Incorporated | Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 vrtx.com ↗ |
| 2005-01-06 | Vertex Pharmaceuticals Incorporated | Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers vrtx.com ↗ |
| 2004-06-22 | Vertex Pharmaceuticals Incorporated | Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer vrtx.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOZASERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL572878 ↗ |
| Known as | MK-0457 | “MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.” PMID 22772060 ↗ Jul 2012 |
| Known as | TOZASERTIB LACTATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL572878 ↗ |
| Known as | VX-680 | “In this study, we examined the intracellular signaling of Aurora kinases inhibitor, MK-0457 (VX-680), in BCR-ABL positive cell lines and in primary samples.” PMID 20563869 ↗ Jun 20101“MK0457, VX-680 (Aurora Kinase Inhibitor)” NCT00099346 ↗ |
| Known as | VX-680 LACTATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL572878 ↗ |
| Action | Inhibit | “Aurora Kinase Inhibitor” NCT00099346 ↗ |
| Modality | Small molecule | — CHEMBL572878 ↗ |
| Route | Other | “Administered as a 5-Day Continuous Infusion” NCT00099346 ↗ |
| Target | ABL1 | “MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant” PMID 25127392 ↗ Aug 2014 |